On November 11, Intuitive Surgical fell 3.14% in Regular Trading, trading at $445.685 per share, with turnover of $178 million.
The clearest identified catalyst remains continued market digestion of the company’s recent quarterly update: while third-quarter adjusted EPS of $3.00 and revenue of $3.049 billion both exceeded expectations, management tightened its outlook for robot-assisted procedure growth, with investors focusing on moderating momentum in the U.S. business.
Recent follow-up developments, including a board appointment and multiple analyst target-price changes, have not fully offset that pressure. The company previously indicated global da Vinci procedure growth would trend closer to the midpoint of its 14% to 15% range, with U.S. procedure growth at 10% versus 20% outside the U.S., reinforcing the debate between strong current results and a slower growth trajectory.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments